cilostazol has been researched along with Innate Inflammatory Response in 30 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cilostazol regimen, attenuated prenatal VPA exposure associated hyperlocomotion, social interaction deficits, repetitive behavior, and anxiety." | 8.02 | Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder. ( Kulkarni, GT; Luhach, K; Sharma, B; Singh, VP, 2021) |
| "These data provided insights into the mechanism underlying the cardioprotective effect of cilostazol in CYP-treated rats through upregulation of SIRT1 signaling, suggesting that cilostazol might be a candidate modality for CYP-induced cardiotoxicity." | 8.02 | Cilostazol preconditioning alleviates cyclophosphamide-induced cardiotoxicity in male rats: Mechanistic insights into SIRT1 signaling pathway. ( Elrashidy, RA; Hasan, RA, 2021) |
| "We previously reported the anti-inflammatory effects of cilostazol, a selective inhibitor of phosphodiesterase 3, and two antioxidants, enzymatically modified isoquercitrin and α-lipoic acid in a dextran sodium sulphate-induced colitis mouse model." | 7.85 | Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation. ( Hayashi, SM; Hippo, Y; Kangawa, Y; Kihara, T; Maruyama, K; Nakamura, M; Ochiai, M; Okamoto, M; Shibutani, M; Yoshida, T, 2017) |
| "The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits." | 7.81 | Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015) |
| "Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 7.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
| "Cilostazol treatment started after 30 days for C+CILO and HCD+CILO groups." | 5.72 | Cilostazol attenuates cardiac oxidative stress and inflammation in hypercholesterolemic rats. ( Alexandre-Santos, B; Autran, LJ; Brazão, SC; Brito, FCF; de Assis Pereira, NC; de Oliveira Lopes, R; Frantz, EDC; Lima, GF; Mendes, ABA; Motta, NAV; Scaramello, CBV, 2022) |
| "Cilostazol (CTZ) is a phosphodiesterase Ш inhibitor, it is a potent vasodilator and antiplatelet drug." | 5.72 | Ellagic acid and cilostazol ameliorate amikacin-induced nephrotoxicity in rats by downregulating oxidative stress, inflammation, and apoptosis. ( Khattab, MI; Khorshid, NE; Saeed, ZM; Salem, AE, 2022) |
| "Treatment with cilostazol significantly reduced the ROS levels in the AqH compared to the diabetic rats." | 5.51 | Cilostazol Attenuates Retinal Oxidative Stress and Inflammation in a Streptozotocin-Induced Diabetic Animal Model. ( Chang, SW; Huang, YH; Lin, CW; Wang, LC; Yang, CH; Yang, CM; Yang, WS; Yeh, PT, 2019) |
| "The cilostazol regimen, attenuated prenatal VPA exposure associated hyperlocomotion, social interaction deficits, repetitive behavior, and anxiety." | 4.02 | Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder. ( Kulkarni, GT; Luhach, K; Sharma, B; Singh, VP, 2021) |
| "These data provided insights into the mechanism underlying the cardioprotective effect of cilostazol in CYP-treated rats through upregulation of SIRT1 signaling, suggesting that cilostazol might be a candidate modality for CYP-induced cardiotoxicity." | 4.02 | Cilostazol preconditioning alleviates cyclophosphamide-induced cardiotoxicity in male rats: Mechanistic insights into SIRT1 signaling pathway. ( Elrashidy, RA; Hasan, RA, 2021) |
| "Mice were administered rosuvastatin alone, cilostazol alone or rosuvastatin and cilostazol in combination, and then injected with LPS or TNF to induce acute inflammation." | 3.91 | Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model. ( Cho, O; Heo, TH; Jang, YJ; Park, KY, 2019) |
| "Mice were orally administered cilostazol plus pravastatin (CILOP) or cilostazol plus rosuvastatin (CILOR), clopidogrel plus pravastatin (CLOP), or clopidogrel plus rosuvastatin (CLOR); then, acute inflammation was induced by the injection of lipopolysaccharide (LPS) or TNF." | 3.91 | A Comparison of the Anti-Inflammatory Effects of Four Combined Statin and Antiplatelet Therapies on Tumor Necrosis Factor-Mediated Acute Inflammation in vivo. ( Cho, O; Heo, TH; Kim, HS; Park, KY, 2019) |
| "We previously reported the anti-inflammatory effects of cilostazol, a selective inhibitor of phosphodiesterase 3, and two antioxidants, enzymatically modified isoquercitrin and α-lipoic acid in a dextran sodium sulphate-induced colitis mouse model." | 3.85 | Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation. ( Hayashi, SM; Hippo, Y; Kangawa, Y; Kihara, T; Maruyama, K; Nakamura, M; Ochiai, M; Okamoto, M; Shibutani, M; Yoshida, T, 2017) |
| " We performed cognitive behavioral tests, including the water maze task, odor discrimination task, and novel object test; histological investigation of neuroinflammation, oligodendrocytes, myelin basic protein, and nodal or paranodal proteins at the nodes of Ranvier; and serial diffusion tensor imaging." | 3.83 | Characterization of White Matter Injury in a Rat Model of Chronic Cerebral Hypoperfusion. ( Back, DB; Choi, BR; Choi, DH; Han, JS; Han, SH; Kang, CH; Kim, BR; Kim, DH; Kim, HY; Kwon, KJ; Lee, J; Moon, WJ; Shin, CY, 2016) |
| "The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits." | 3.81 | Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015) |
| " Long-term administration of cilostazol is more effective in reducing neointimal formation at non-overlapping segments of BESs in a porcine coronary model." | 3.79 | The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model. ( Ahn, Y; Cho, JG; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, JM; Kim, KH; Lee, KH; Lim, KS; Park, DS; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS, 2013) |
| "Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 3.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
| "Cilostazol (CLS) has shown antidepressant effect in cardiovascular patients, post-stroke depression, and animal models through its neurotrophic and antiinflammatory activities." | 3.01 | Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder. ( Abdallah, MS; Abo Mansour, HE; Elsawah, HK; Elsokary, MA; Mansour, NO; Mosalam, EM; Omara-Reda, H; Ramadan, AN; Zaki, SA, 2021) |
| "Initiating mechanisms of migraine headache remain poorly understood and a biomarker of migraine does not exist." | 2.90 | Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. ( Amin, FM; Ashina, M; Birgens, H; Christensen, CE; Daldrup-Link, H; Fliedner, FP; Khan, S; Kjær, A; Larsson, HBW; Lindberg, U; Olinger, ACR; Tolnai, D; Younis, S, 2019) |
| "Cilostazol treatment started after 30 days for C+CILO and HCD+CILO groups." | 1.72 | Cilostazol attenuates cardiac oxidative stress and inflammation in hypercholesterolemic rats. ( Alexandre-Santos, B; Autran, LJ; Brazão, SC; Brito, FCF; de Assis Pereira, NC; de Oliveira Lopes, R; Frantz, EDC; Lima, GF; Mendes, ABA; Motta, NAV; Scaramello, CBV, 2022) |
| "Cilostazol (CTZ) is a phosphodiesterase Ш inhibitor, it is a potent vasodilator and antiplatelet drug." | 1.72 | Ellagic acid and cilostazol ameliorate amikacin-induced nephrotoxicity in rats by downregulating oxidative stress, inflammation, and apoptosis. ( Khattab, MI; Khorshid, NE; Saeed, ZM; Salem, AE, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease linked to insulin resistance, oxidative stress, and cytokine imbalance." | 1.56 | Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats. ( Abdel-Latif, RG; El-Deen, RM; Heeba, GH; Khalifa, MMA, 2020) |
| "Treatment with cilostazol significantly reduced the ROS levels in the AqH compared to the diabetic rats." | 1.51 | Cilostazol Attenuates Retinal Oxidative Stress and Inflammation in a Streptozotocin-Induced Diabetic Animal Model. ( Chang, SW; Huang, YH; Lin, CW; Wang, LC; Yang, CH; Yang, CM; Yang, WS; Yeh, PT, 2019) |
| "Induction of liver fibrosis in TAA-treated rats was observed as evidenced by the biochemical and histopathological findings." | 1.51 | Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers. ( Abdel Rahman, RF; Arbid, MS; Badawi, M; El Awdan, SA; El Marasy, SA; Hegazy, RR; Ibrahim, HM, 2019) |
| "Cilostazol was administered to the rats through oral gavage at 4 hours before the measurements." | 1.40 | Cilostazol strengthens the endothelial barrier of postcapillary venules from the rat mesentery in situ. ( Kajimura, M; Morikawa, T; Suematsu, M; Sugiura, Y; Takenouchi, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.00) | 29.6817 |
| 2010's | 18 (60.00) | 24.3611 |
| 2020's | 9 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Luhach, K | 1 |
| Kulkarni, GT | 1 |
| Singh, VP | 1 |
| Sharma, B | 1 |
| Abdallah, MS | 1 |
| Ramadan, AN | 1 |
| Omara-Reda, H | 1 |
| Mansour, NO | 1 |
| Elsokary, MA | 1 |
| Elsawah, HK | 1 |
| Zaki, SA | 1 |
| Abo Mansour, HE | 1 |
| Mosalam, EM | 1 |
| de Oliveira Lopes, R | 1 |
| Lima, GF | 1 |
| Mendes, ABA | 1 |
| Autran, LJ | 1 |
| de Assis Pereira, NC | 1 |
| Brazão, SC | 1 |
| Alexandre-Santos, B | 1 |
| Frantz, EDC | 1 |
| Scaramello, CBV | 1 |
| Brito, FCF | 1 |
| Motta, NAV | 1 |
| Saeed, ZM | 1 |
| Khattab, MI | 1 |
| Khorshid, NE | 1 |
| Salem, AE | 1 |
| Othman, EM | 1 |
| Habib, HA | 1 |
| Zahran, ME | 1 |
| Amin, A | 1 |
| Heeba, GH | 2 |
| Park, JB | 1 |
| Ko, K | 1 |
| Baek, YH | 1 |
| Kwon, WY | 1 |
| Suh, S | 1 |
| Han, SH | 3 |
| Kim, YH | 1 |
| Kim, HY | 2 |
| Yoo, YH | 1 |
| Lee, HR | 1 |
| Park, KY | 3 |
| Jeong, YJ | 1 |
| Heo, TH | 3 |
| El-Deen, RM | 1 |
| Abdel-Latif, RG | 1 |
| Khalifa, MMA | 1 |
| Elrashidy, RA | 1 |
| Hasan, RA | 1 |
| El Awdan, SA | 2 |
| Amin, MM | 1 |
| Hassan, A | 1 |
| Mohamed, MZ | 1 |
| Hafez, HM | 1 |
| Zenhom, NM | 1 |
| Mohammed, HH | 1 |
| Yeh, PT | 1 |
| Huang, YH | 1 |
| Chang, SW | 1 |
| Wang, LC | 1 |
| Yang, CM | 1 |
| Yang, WS | 1 |
| Lin, CW | 1 |
| Yang, CH | 1 |
| Cho, O | 2 |
| Jang, YJ | 1 |
| Kim, HS | 1 |
| Abdel Rahman, RF | 1 |
| Ibrahim, HM | 1 |
| Hegazy, RR | 1 |
| El Marasy, SA | 1 |
| Badawi, M | 1 |
| Arbid, MS | 1 |
| Khan, S | 1 |
| Amin, FM | 1 |
| Fliedner, FP | 1 |
| Christensen, CE | 1 |
| Tolnai, D | 1 |
| Younis, S | 1 |
| Olinger, ACR | 1 |
| Birgens, H | 1 |
| Daldrup-Link, H | 1 |
| Kjær, A | 1 |
| Larsson, HBW | 1 |
| Lindberg, U | 1 |
| Ashina, M | 1 |
| Wada, T | 1 |
| Onogi, Y | 1 |
| Kimura, Y | 1 |
| Nakano, T | 1 |
| Fusanobori, H | 1 |
| Ishii, Y | 1 |
| Sasahara, M | 1 |
| Tsuneki, H | 1 |
| Sasaoka, T | 1 |
| Sugiura, Y | 1 |
| Morikawa, T | 1 |
| Takenouchi, T | 1 |
| Suematsu, M | 1 |
| Kajimura, M | 1 |
| Shimamura, N | 1 |
| Ohkuma, H | 1 |
| Lee, K | 1 |
| Yoo, SY | 1 |
| Suh, J | 1 |
| Park, KH | 2 |
| Park, Y | 1 |
| Tantry, US | 1 |
| Park, KS | 1 |
| Kang, WC | 1 |
| Shin, DH | 1 |
| Lee, C | 1 |
| Choi, SW | 1 |
| Lee, JH | 1 |
| Cho, YH | 1 |
| Lee, NH | 1 |
| Jeong, MH | 2 |
| Ahn, Y | 2 |
| Kubica, J | 1 |
| Gurbel, PA | 1 |
| Park, JH | 1 |
| Jeong, YH | 1 |
| Kumar, A | 2 |
| Jaggi, AS | 1 |
| Singh, N | 1 |
| Koh, JS | 1 |
| Yi, CO | 1 |
| Heo, RW | 1 |
| Ahn, JW | 1 |
| Park, JR | 1 |
| Lee, JE | 1 |
| Kim, JH | 3 |
| Hwang, JY | 1 |
| Roh, GS | 1 |
| Wang, Y | 1 |
| Bai, L | 1 |
| Lin, Y | 1 |
| Chen, Y | 1 |
| Guan, H | 1 |
| Zhu, N | 1 |
| Li, Y | 1 |
| Gao, S | 1 |
| Sun, L | 1 |
| Zhao, S | 1 |
| Fan, J | 1 |
| Liu, E | 1 |
| Choi, BR | 1 |
| Kim, DH | 1 |
| Back, DB | 1 |
| Kang, CH | 1 |
| Moon, WJ | 1 |
| Han, JS | 1 |
| Choi, DH | 1 |
| Kwon, KJ | 1 |
| Shin, CY | 1 |
| Kim, BR | 1 |
| Lee, J | 1 |
| Kangawa, Y | 1 |
| Yoshida, T | 1 |
| Maruyama, K | 1 |
| Okamoto, M | 1 |
| Kihara, T | 1 |
| Nakamura, M | 1 |
| Ochiai, M | 1 |
| Hippo, Y | 1 |
| Hayashi, SM | 1 |
| Shibutani, M | 1 |
| Mendes, JB | 1 |
| Campos, PP | 1 |
| Rocha, MA | 1 |
| Andrade, SP | 1 |
| Kim, JM | 1 |
| Park, DS | 1 |
| Lim, KS | 1 |
| Lee, KH | 1 |
| Sim, DS | 1 |
| Yoon, HJ | 1 |
| Yoon, NS | 1 |
| Kim, KH | 1 |
| Park, HW | 1 |
| Hong, YJ | 1 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Watanabe, T | 1 |
| Zhang, N | 1 |
| Liu, M | 1 |
| Tanaka, R | 1 |
| Mizuno, Y | 1 |
| Urabe, T | 1 |
| Agrawal, NK | 1 |
| Maiti, R | 1 |
| Dash, D | 1 |
| Pandey, BL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Randomized, Placebo-Controlled Pilot Study of the Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder[NCT04069819] | 80 participants (Actual) | Interventional | 2019-08-01 | Completed | |||
| Investigation of Vascular Inflammation in Migraine Without Aura Using Molecular Nano-imaging and Black Blood Imaging MRI[NCT02549898] | 34 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for cilostazol and Innate Inflammatory Response
| Article | Year |
|---|---|
Phenotypic transformation of smooth muscle in vasospasm after aneurysmal subarachnoid hemorrhage.
Topics: Animals; Cilostazol; Humans; Inflammation; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phenot | 2014 |
4 trials available for cilostazol and Innate Inflammatory Response
| Article | Year |
|---|---|
Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder.
Topics: Adult; Cilostazol; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Escit | 2021 |
Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging.
Topics: Adult; Animals; Brain; Cilostazol; Dextrans; Female; Humans; Inflammation; Macrophages; Magnetic Res | 2019 |
Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammati
Topics: Acute Coronary Syndrome; Aged; Cilostazol; Drug Administration Schedule; Female; Humans; Inflammatio | 2015 |
Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients.
Topics: Anti-Inflammatory Agents; Antioxidants; Blood Sedimentation; C-Reactive Protein; Cardiovascular Dise | 2007 |
25 other studies available for cilostazol and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder.
Topics: Animals; Anticonvulsants; Anxiety; Autism Spectrum Disorder; Behavior, Animal; Biomarkers; Brain; Ci | 2021 |
Cilostazol attenuates cardiac oxidative stress and inflammation in hypercholesterolemic rats.
Topics: Animals; Antioxidants; Cilostazol; Inflammation; Lipids; Male; NF-E2-Related Factor 2; NF-kappa B; O | 2022 |
Ellagic acid and cilostazol ameliorate amikacin-induced nephrotoxicity in rats by downregulating oxidative stress, inflammation, and apoptosis.
Topics: Amikacin; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Cilostazol; Ellagic Acid; In | 2022 |
Mechanistic Protective Effect of Cilostazol in Cisplatin-Induced Testicular Damage via Regulation of Oxidative Stress and TNF-α/NF-κB/Caspase-3 Pathways.
Topics: Animals; Caspase 3; Cilostazol; Cisplatin; Inflammation; Male; NF-kappa B; Oxidative Stress; Pentoxi | 2023 |
Pharmacological Prevention of Ectopic Erythrophagocytosis by Cilostazol Mitigates Ferroptosis in NASH.
Topics: Animals; Cilostazol; Ferroptosis; Humans; Inflammation; Mice; Non-alcoholic Fatty Liver Disease | 2023 |
Comparative effectiveness of different antiplatelet agents at reducing TNF-driven inflammatory responses in a mouse model.
Topics: Animals; Cilostazol; Clopidogrel; Disease Models, Animal; Inflammation; Inflammation Mediators; Male | 2020 |
Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats.
Topics: Animals; Antioxidants; Biomarkers; Cilostazol; Diet, High-Fat; Fatty Liver; Inflammation; Insulin; I | 2020 |
Cilostazol preconditioning alleviates cyclophosphamide-induced cardiotoxicity in male rats: Mechanistic insights into SIRT1 signaling pathway.
Topics: Animals; Antioxidants; Apoptosis; Bronchodilator Agents; Cardiotoxicity; Cilostazol; Cyclophosphamid | 2021 |
Cilostazol attenuates indices of liver damage induced by thioacetamide in albino rats through regulating inflammatory cytokines and apoptotic biomarkers.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Caspase 3; Cilostazol; Cytokines; Cytoprotection; Gene | 2018 |
Cilostazol alleviates streptozotocin-induced testicular injury in rats via PI3K/Akt pathway.
Topics: Animals; Cilostazol; Diabetes Complications; Diabetes Mellitus, Experimental; Glutathione; Heme Oxyg | 2018 |
Cilostazol Attenuates Retinal Oxidative Stress and Inflammation in a Streptozotocin-Induced Diabetic Animal Model.
Topics: Animals; Aqueous Humor; Blood Glucose; Blotting, Western; Chemokine CCL2; Chemokine CX3CL1; Cilostaz | 2019 |
Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model.
Topics: Animals; Anti-Inflammatory Agents; Cilostazol; Disease Models, Animal; Drug Therapy, Combination; He | 2019 |
A Comparison of the Anti-Inflammatory Effects of Four Combined Statin and Antiplatelet Therapies on Tumor Necrosis Factor-Mediated Acute Inflammation in vivo.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Cilostazol; Clopidogrel; Disease Models, An | 2019 |
Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers.
Topics: Animals; Apoptosis; Biomarkers; Cilostazol; Cyclic AMP; Inflammation; Liver; Liver Cirrhosis; Oxidat | 2019 |
Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Chronic Disease; Cilostazol; Diabetes Mellitus, E | 2013 |
Cilostazol strengthens the endothelial barrier of postcapillary venules from the rat mesentery in situ.
Topics: Animals; Cilostazol; Endothelium, Vascular; Hemodynamics; Histamine; Inflammation; Male; Mesentery; | 2014 |
Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia.
Topics: Animals; Blood Glucose; Body Weight; Brain Chemistry; Cilostazol; Dementia, Vascular; Diabetes Melli | 2015 |
Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice.
Topics: Animals; Antibiotics, Antineoplastic; Blotting, Western; Cardiomyopathies; Cilostazol; Doxorubicin; | 2015 |
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomarkers; Cilostazol; Drug Therapy, Combination; Hy | 2015 |
Characterization of White Matter Injury in a Rat Model of Chronic Cerebral Hypoperfusion.
Topics: Animals; Behavior, Animal; Brain Ischemia; Carotid Stenosis; Chronic Disease; Cilostazol; Cognition; | 2016 |
Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation.
Topics: Animals; Azoxymethane; Carcinogens; Cell Proliferation; Cilostazol; Colitis; Colonic Neoplasms; Enzy | 2017 |
Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice.
Topics: Animals; Cilostazol; Disease Models, Animal; Fibrosis; Inflammation; Male; Mice; Mice, Inbred BALB C | 2009 |
The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model.
Topics: Absorbable Implants; Animals; Aspirin; Cilostazol; Clopidogrel; Coated Materials, Biocompatible; Cor | 2013 |
Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion.
Topics: Animals; Apoptosis; Brain; Brain Ischemia; Chronic Disease; Cilostazol; Cyclic AMP Response Element- | 2006 |